Log In Sign Up

ECTRIMS 2019 - MSBase presentations

Oral Presentations

Liesbet Peeters, Rehabilitation and MS-Centre Overpelt, Belgium

Introducing machine learning for full MS patient trajectories improves predictions for disability score progression

 

Sifat Sharmin, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia

Predicting long-term sustained disability progression in multiple sclerosis

 

Poster Presentations

Ilya Kister, New York University School of Medicine, USA

Does Multiple Sclerosis Severity Score (MSSS) provide additional prognostic value to the ‘MSBase model’ of individual treatment response in Multiple Sclerosis

 

Helmut Butzkueven, MSBase collaboration with Merck

Real-world experience with Cladribine in MSBase registry

 

Charles Malpas, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia

Disease reactivation following fingolimod cessation

 

Nahid Moradi, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia

MS cohorts and treatment utilization in academic centres in the Middle East 

 

Helmut Butzkueven, MSBase collaboration with Roche

Real-world experience with Ocrelizumab in MSBase registry

 

Izanne Roos, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia

Determinants of Therapeutic Lag in Relapsing Multiple Sclerosis

Therapeutic Lag in Relapsing Multiple Sclerosis

 

Charles Malpas, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia

Aggressive form of multiple sclerosis can be predicted early after disease onset

 

Sifat Sharmin, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia

Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

 

Francesca Bovis, MSBase fellow, supervised by Claudio Solaro, Centro Sclerosi Multipla ASL3 Genovese, Italy

Personalizing treatment effect based on patient’s baseline profile: A statistical modelling approach applied to randomized clinical trial and observational study data

 

Tomas Kalincik, The Royal Melbourne Hospital, Australia

Modifiers of the effectiveness of MS immunotherapies

 

Tomas Uher, supervised by Tomas Kalincik, The Royal Melbourne Hospital, Australia

Disability trajectories in relapsing-remitting multiple sclerosis (ePoster)

 

 

Back